Dynavax Technologies Corporation
Dynavax Technologies — Q1 2025 Earnings Presentation
24 slides from Dynavax Technologies's earnings presentation, May 6, 2025
Slide 1: Corporate Presentation
Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases May 2025 Nasdaq: DVAX
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's expected financial results and market
Slide 3: Dynavax Core Strategic Priorities
Drive Growth in HEPLISAV-B • Achieve at least 60% total market share by 2030 • Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation • Leverage foundational commercial asset to support company growth and pipeline development Dynavax Advance Di
Slide 4: Executing on Our Strategy: Q1 '25 Highlights
Executing on Our Strategy: Q1 ’25 Highlights HEPLISAV-B Q1 ’25 net product revenue: HEPLISAV-B total U.S. market share (as of Q1 ‘25): Achieved highest ever first $65M, up 36% YoY vs. $48M in Q1 ‘24 ~43% in Q1 ’25 vs. ~41% in Q1‘ 24 quarter HEPLISAV-B net Long-term guidance: product revenue Hepatiti
Slide 5: CpG 1018 Adjuvant: Well-defined MoA and Clinical Profile
CpG 1018® Adjuvant: Well-defined MoA and Clinical Profile Proprietary CpG 1018 Mechanism of Action Clinically Proven Profile adjuvant selectively and • CpG 1018 adjuvant is a • Faster and consistently higher rates optimally activates TLR9 – synthetic form of DNA that of protection in HEPLISAV-B, an
Slide 6: HEPLISAV-B
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] © Copyright DYNAVAX 2025 6|
Slide 7: HEPLISAV-B Clinical Outcomes
Primary Endpoint Results: HEPLISAV-B Study 2 per protocol population (ages 40-70)1 Primary Primary Clinical Outcomes 100% (N=1,482) endpoint endpoint 90% Higher and faster rates of protection 80% HEPLISAV-B provided significantly higher rates of protection than Engerix-B 70% at every time point in c
Slide 8: Continued HEPLISAV-B Growth: Revenue & Market Share
Continued HEPLISAV-B Growth: Revenue & Market Share Sequential Q1 HEPLISAV-B HEPLISAV-B Vaccine Annual Net 300 Total U.S. Market Share1 Product Revenue ($M)2 Achieved record 50% annual revenue in 250 2024 of $268M 200 43% 150 41% 40% 37% 100 50 36 62 126 213 268 30% 0 Q1'23 Q1'24 Q1'25 2020 36 2021
Slide 9: HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030
HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 Peak Market Expanding Market Opportunity Through 2030 Durable Long Term Market Opportunity Maintained Through 2040 in 2030 Represents a double-digit CAGR for HEPLISAV-B product net sales out to 2030 >$900M • Ongoing penetr
Slide 10: HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030
HEPLISAV-B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 HEPLISAV-B is the market share leader in projected largest growth segments (Retail and Prioritized IDNs) 2024 Market Size: ~$615 M1 2030 Projected Market Size: >$900 M2 Dialysis3 5% Prioritized IDN/ Dialysis3 Clinics4 6% 3
Slide 11: Vaccine Development Pipeline
Vaccine Development Pipeline © Copyright DYNAVAX 2025 11 |
Slide 12: Shingles Vaccine Program: New Options Needed
Shingles Vaccine Program: New Options Needed Current Market-Leading Vaccine Associated with Adverse Events1 Herpes Zoster (shingles) is an extremely painful consequence Program Status: of the reactivation of a latent varicella-zoster virus (VZV), the • Completed enrollment in Part 1 of Phase 1/2 tri
Slide 13: Shingles Vaccine Program: Path to Establishing Proof-of-Concept
Shingles Vaccine Program: Path to Establishing Proof-of-Concept for a Differentiated and Best-in-Class Shingles Vaccine Key Trial Objectives / Next Steps PHASE 1 PHASE 1/2 FUTURE DEVELOPMENT CLINICAL TRIAL CLINICAL TRIAL Established initial proof-of-principle for o Demonstrate similar immunogenicity
Slide 14: Shingles Vaccine Program: Z-1018 Improved Tolerability and Similar Immunogenicity
Shingles Vaccine Program: Z-1018 Demonstrated Improved Tolerability and Similar Immunogenicity Compared to Shingrix in Phase 1 Tolerability Immunogenicity Rate of moderate/severe Vaccine Response Rate (VRR)2 Post Injection Reactions (PIRs)1 Local PIRs Systemic PIRs Anti-gE Antibodies CD4+ T-cells 10
Slide 15: Plague Vaccine Program
Plague Vaccine Program Phase 2 program conducted in collaboration with, and funded by, the U.S. DoD Program Status: Government agencies research and stockpile medical • Based on the results from a randomized, active- countermeasures – biologics, drugs, devices – which may be controlled Phase 2 clini
Slide 16: Preclinical & Early-Stage Programs
Preclinical & Early-Stage Programs Pandemic Influenza Adjuvant Lyme Disease Vaccine One of the most persistent and unpredictable global Bacterial infection that is the most common vector- health threats borne illness in Northern Hemisphere Opportunity: Adjuvants, like CpG 1018 play an essential role
Slide 17: Financial Highlights
Financial Highlights © Copyright DYNAVAX 2025 17 |
Slide 18: Q1 2025 Financial Summary
Q1 2025 Financial Summary Financial Results ($ millions) Q1 2025 Q1 2024 % Change Total Revenues 68.2 50.8 34% HEPLISAV-B Net Product Revenue 65.0 47.8 36% Other Revenue 3.2 2.9 9% Cost of Sales - Product 13.8 11.0 26% HEPLISAV-B Gross Margin % 79% 77% 2% R&D Expenses 19.4 13.5 43% SG&A Expenses 47.
Slide 19: Creating Value through Disciplined and Balanced Capital Allocation Strategy
Creating Value through Disciplined and Balanced Capital Allocation Strategy Our capital allocation priorities include: 01 02 03 04 Maximizing Investing in Accessing late- Opportunistically HEPLISAV-B pipeline leveraging stage assets in return capital to through targeted CpG 1018 infectious diseases
Slide 20: Reiterating Full Year 2025 Financial Guidance
Reiterating Full Year 2025 Financial Guidance1 HEPLISAV-B Adjusted EBITDA 3 Net Product Revenue (Excluding stock-based compensation) $305 M - $325 M > $75 M Up 17% YoY 2 Up 45% YoY 1. FY 2025 financial guidance based on the Company’s current operating plan as of May 6, 2025 2. The percent change of
Slide 21: Dynavax Core Strategic Priorities
Drive Growth in HEPLISAV-B • Achieve over 60% total market share by 2030 • Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation • Leverage foundational commercial asset to support company growth and pipeline development Dynavax Advance Differ
Slide 22: Appendix: Non-GAAP Reconciliations
Appendix: Non-GAAP Reconciliations © Copyright DYNAVAX 2025 22 |
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about Adjusted EBITDA, a non-GAAP financial measure. We believe the presentation of this non-GAAP financial measure, when viewed with our results under GAAP and the accompanying re
Slide 24: Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA
DYNAVAX TECHNOLOGIES CORPORATION RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA (In thousands) (Unaudited) Three Months Ended March 31, 2025 2024 GAAP net loss $ (96,099) $ (8,721) Adjustments: Depreciation & amortization 374 375 Interest income (7,739) (9,468) Interest expense 1,692 1,